 | |
 | |
| Clinical data | |
|---|---|
| Other names | 6-n-propylthiouracil (PROP) |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682465 |
| Pregnancy category | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 80%-95% |
| Metabolism | ? |
| Eliminationhalf-life | 2 hours |
| Excretion | ? |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.000.095 |
| Chemical and physical data | |
| Formula | C7H10N2OS |
| Molar mass | 170.23 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 219 to 221 °C (426 to 430 °F) |
| |
| |
| (verify) | |
Propylthiouracil (PTU) is a medication used to treathyperthyroidism.[3] This includes hyperthyroidism due toGraves' disease andtoxic multinodular goiter.[3] In athyrotoxic crisis it is generally more effective thanmethimazole.[3] Otherwise it is typically only used when methimazole, surgery, andradioactive iodine is not possible.[3] It is takenby mouth.[3]
Common side effects include itchiness, hair loss, parotid swelling, vomiting, muscle pains, numbness, and headache.[3] Other severe side effects includeliver problems andlow blood cell counts.[3] Use during pregnancy may harm the baby.[3] Propylthiouracil is in theantithyroid family of medications.[4] It works by decreasing the amount ofthyroid hormone produced by thethyroid gland and blocking the conversion ofthyroxine (T4) totriiodothyronine (T3).[3]
Propylthiouracil came into medical use in the 1940s.[5] It is on theWorld Health Organization's List of Essential Medicines.[6]
Propylthiouracil is generally well tolerated, with side effects occurring in one of every 100 patients.[citation needed] The most common side effects are related to the skin and include rash, itching, hives, abnormal hair loss, and skin pigmentation.[citation needed] Other common side effects are swelling, nausea, vomiting, heartburn, loss of taste, joint or muscle aches, numbness and headache, allergic reactions, and hair whitening.[citation needed]
Its notable side effects include a risk ofagranulocytosis andaplastic anemia. On 3 June 2009, theFDA published an alert "notifying healthcare professionals of the risk of serious liver injury, including liver failure and death, with the use of propylthiouracil."[7] As a result, propylthiouracil is no longer recommended in non-pregnant adults and in children as the front line antithyroid medication.[8]
One possible side effect isagranulocytosis,[9] a decrease of white blood cells in the blood. Symptoms and signs of agranulocytosis include infectious lesions of the throat, the gastrointestinal tract, and skin with an overall feeling of illness and fever. A decrease in blood platelets (thrombocytopenia) also may occur. Since platelets are important for the clotting of blood, thrombocytopenia may lead to problems with excessive bleeding. Side effects are suspected and the drug is sometimes discontinued if the patient complains of recurrent episodes of sore throat.
Another life-threatening side effect is sudden, severe,fulminant liver failure resulting in death or the need for a liver transplantation, which occurs in up to 1 in 10,000 people taking propylthiouracil. Unlike agranulocytosis which most commonly occurs in the first three months of therapy, this side effect may occur at any time during treatment.[8]
Propylthiouracil is classified asDrug Class D in pregnancy. Class D signifies there is positive evidence of human fetal risk. The maternal benefit may outweigh fetal risk in life-threatening situations.[10] PTU is preferred overmethimazole (which is also a class D) only in the first trimester of pregnancy and in women who may become pregnant because of the increased risk of teratogenicity of methimazole during critical organogenesis. In the second and third trimester, this risk is diminished andmethimazole is preferred to avoid the risk of liver complications from PTU in the mother.[8]
The primary effect on the fetus from transplacental passage of PTU is the production of a mild hypothyroidism when the drug is used close to term. This usually resolves within a few days without treatment. The hypothyroid state may be observed as a goiter in the newborn, and is the result of increased levels of fetal pituitary thyrotropin.[11] The incidence of fetal goiter after PTU treatment in reported cases is approximately 12%.
PTU inhibits the enzymethyroperoxidase, which normally acts in thyroid hormone synthesis by oxidizing the anioniodide (I−) toiodine (I0), facilitating iodine's addition to tyrosine residues on the hormone precursorthyroglobulin. This is one of the essential steps in the formation ofthyroxine (T4).[12]
PTU does not inhibit the action of thesodium-dependent iodide transporter located on follicular cells' basolateral membranes. Inhibition of this step requires competitive inhibitors, such asperchlorate andthiocyanate.
PTU also acts by inhibiting the enzyme 5'-deiodinase (tetraiodothyronine 5' deiodinase), which converts T4 to the more active form T3. (This is in contrast tomethimazole, which shares propylthiouracil's central mechanism, but not its peripheral one.)
It is important to recognize that these enzymes only work on the conjugated tyrosine molecules of T3 and T4: a completely different enzyme family is responsible for the deiodinase activity of iodized single tyrosine molecules within the thyroid follicular cells. For information on that enzyme family, seeIodotyrosine deiodinase.
The administration is oral, with peak serum concentrations occurring in one hour, and actively concentrated to the thyroid gland. Depending on several patient variables, however, euthyroid status may not be achieved until 2–4 months after treatment initiation. Of note, the drug is approximately 70% protein-bound and significantly ionized at normal physiologic pH, while the antithyroid agentmethimazole is substantially less protein bound. However, both are equally transferred across the placenta.[13]
The plasma half-life is one hour and is not altered appreciably by the thyroid status of the patient. Due to the concentration in the thyroid, however, dosing intervals may last 8 hours or longer. Less than 10% of the drug is excreted unchanged, with the remaining fraction undergoing extensive hepatic metabolism viaglucuronidation.
Propylthiouracil can be prepared fromethyl 3-oxohexanoate andthiourea.[14]
Propylthiouracil, together withphenylthiocarbamide (PTC), are known to have bitter taste.[15] However, it seems thepropensity for tasting these compounds is genetically based and the bitter taste is likely to be engendered by thethiocyanate moiety, also present in PTC.[15]
It was approved by the United StatesFood and Drug Administration in 1947.
